Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma

Ohyashiki, Kazuma; Umezu, Tomohiro; Yoshizawa, Seiichiro; Ito, Yoshikazu; Ohyashiki, Michiyo; Kawashima, Hisashi; Tanaka, Masami; Kuroda, Masahiko; Ohyashiki, Junko H.

doi:10.1371/journal.pone.0016408

Cited by 89 publications

(68 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV infection may increase miR-1290 expression directly or indirectly, since miR-1290 is already increased in CIN1. In order to normalize the miRNA expression level, miR-16 was used as an internal control, as previously reported (13,14,20).…”

Section: Discussionmentioning

confidence: 99%

“…Briefly, 250 µl of serum was homogenized in 750 µl of ISOGEN-LS and 200 µl of chloroform was added to the sample, which was centrifuged. Following additional chloroform extraction and precipitation with isopropanol, the RNA sample was suspended in 20 µl of nuclease-free water (13).…”

Section: Comprehensive Analysis Of Serum Mirnas By Microarraymentioning

confidence: 99%

“…The -ΔΔCt value was calculated by subtracting the -ΔCt value of a normal sample from the respective -ΔCt values of the patient samples. Expression of miR-1290 was normalized using the 2 -ΔΔCt method (13,14). The miR-1290 expression profile was used to create a receiver operating characteristic (ROC) curve, which is a graphical plot of the true-positive vs. the false-positive rate.…”

Section: Comprehensive Analysis Of Serum Mirnas By Microarraymentioning

confidence: 99%

See 2 more Smart Citations

Profiling analysis of circulating microRNA expression in cervical cancer

Nagamitsu

Nishi

Sasaki

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. MicroRNA (miRNA) expression is altered in cancer cells and is associated with the development and progression of various types of cancer. Accordingly, miRNAs may serve as diagnostic or prognostic biomarkers in cancer patients. In this study, we attempted to analyze circulating exosomal miRNA in patients with cervical cancer. Total RNA was extracted from the serum of healthy subjects, subjects with cervical intraepithelial neoplasia (CIN) and patients with cervical cancer. We first investigated miRNA expression profiles in 6 serum samples from healthy subjects and patients with cervical cancer using the miRCURY LNA microRNA array. miRNAs with significant differences in expression were validated in a larger sample set by quantitative reverse transcription-polymerase chain reaction, using TaqMan gene expression assays. The results of the miRCURY LNA microRNA array indicated that 6 of 1,223 miRNAs found in serum samples from cervical cancer patients and normal controls exhibited a >3.0-fold change in expression level in subjects with cervical cancer, with a P-value of <0.01. In a validation set (n=131) that investigated the expression of 4 of the 6 miRNAs (miR-483-5p, miR-1246, miR-1275 and miR-1290), miR-1290 was found to have significantly higher expression levels in cervical cancer samples (n=45) compared with control samples (n=31). We also found that the median levels of these miRNAs were significantly higher in subjects with cervical cancer (n=45) compared with those in subjects with CIN (n=55). Circulating miRNAs were not correlated with clinicopathological parameters. However, receiver operating characteristic curve analysis suggested that these serum miRNAs may be useful diagnostic markers in cervical cancer. The expression of circulating miR-1290 was significantly higher in the blood of cervical cancer patients compared with that in controls and may thus serve as a useful biomarker in cervical cancer diagnosis. However, larger studies are required to fully elucidate the role of circulating exosomal miRNAs in cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Comprehensive Analysis Of Serum Mirnas By Microarraymentioning

confidence: 99%

Section: Comprehensive Analysis Of Serum Mirnas By Microarraymentioning

confidence: 99%

See 1 more Smart Citation

Profiling analysis of circulating microRNA expression in cervical cancer

Nagamitsu

Nishi

Sasaki

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…As a result decreased expression of miRNAs would be observed in plasma. [45][46][47] Two single miRNAs, miR449a and miR-1228 showed high sensitivity and specificity in classifying EEC and control samples. Moreover, logistic regression analysis revealed two miRNA signatures: miR-9/ miR-1228 and miR-9/miR-92a, which classified EEC plasma samples with higher accuracy in comparison to single miRNAs.…”

Section: Early Detection and Diagnosismentioning

confidence: 99%

Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients

Torres

Pesci

et al. 2012

Intl Journal of Cancer

132

120

View full text Add to dashboard Cite

The aim of our study was to define tissue and plasma miRNA signatures, which could potentially serve as diagnostic and prognostic markers in endometrioid endometrial cancer (EEC) and to investigate miRNA profiles in regard to clinicopathological characteristics. Tissue and plasma samples were collected from 122 women (77 EEC and 45 controls). Expression profiling of 866 human miRNAs and 89 human viral miRNAs was performed in 24 samples and was followed by qPCR validation in 104 patients. Expression of 16 miRNAs was analyzed in 48 plasma samples. Microarray study revealed regulation of 21 miRNAs in EEC tissues comparing to normal endometrium. Altered expression of 17 miRNAs was confirmed by qPCR performed in 104 tissue samples. Seven miRNAs were upregulated and two were downregulated in EEC plasma samples. Endometrial cancer is the fourth most often diagnosed malignancy in the female population of the developed countries and the most common cancer of the female reproductive tract. In 2008, 82,530 endometrial cancer cases were recorded in Europe.1 Estimated number of new cases diagnosed in 2011 in the United States was 46,470 and was higher than in 2010.2 Data deposited in the Polish Cancer Registry indicated a progressive increase in endometrial cancer incidence over the period between 1999 and 2008.3 Similar trend has been observed in Great Britain. 4 Endometrial cancer is a heterogeneous malignancy comprising many histological types, which differ significantly in terms of pathogenesis, clinical presentation and prognosis. Such heterogeneity impedes development of screening and treatment strategies. Despite a great improvement in endometrial cancer treatment and diagnosis, advanced stages of the disease are still difficult to manage with the 5-year survival rate of $10-29%.5 Increase in the incidence of endometrial cancer and the lack of powerful yet nontoxic treatment strategies indicate the need of developing novel diagnostic, prognostic and treatment strategies for this malignancy.

show abstract

“…An 8-miRNA signature (let-7g, miR-19a, miR-21, miR-23a, miR-27a, miR-34a, miR-127, miR-195) was associated with outcome in DLBCL cases (Roehle et al, 2008), a 21-miRNA signature (including miR-21, miR-23, miR-27a, miR-30e, miR-199b, miR-330) with outcome in de novo DLBCL cases (Lawrie et al, 2009), and a 23-miRNA signature (including let-7a, let-7f, miR-20a, miR-20b, miR-30b, miR-96, miR-195, miR-221*, miR-1260, miR-1274a) with treatment response to chemotherapy in FL cases (Wang et al, 2011b). Differential expression of individual miRNAs has enough power to predict outcome as is the case for miR-18a, miR181a and miR-222 in DLBCL (Alencar et al, 2011), for miR-29 family members in MCL (Zhao et al, 2010) and for miR-92a in plasma of patients afflicted with different types of non-Hodgkin's B cell lymphomas (Ohyashiki et al, 2011). Several mechanistic links have been proposed between these miRNAs and oncogenic pathways.…”

Section: Altered Microrna Expression In B Cell Lymphomasmentioning

confidence: 99%